Venetoclax-resistant secondary AML transformed from CMML responds to lenzilumab BURLINGAME, CA / ACCESS Newswire / November 4, 2025 / Taran Therapeutics ("Taran") a privately ...
Q3 2025 Earnings Call Transcript November 3, 2025 Karyopharm Therapeutics Inc. misses on earnings expectations. Reported EPS ...
Arm lymphedema is a common and sometimes challenging side effect that can occur after breast cancer treatment, causing ...
Researchers at Memorial Sloan Kettering Cancer Center (MSK) have developed some of the first robust laboratory models of a ...
BERLIN -- Administering bone-modifying agents (BMAs) every 24 weeks after long-term use was a safe and effective strategy for patients with bone metastases from breast cancer, and also appeared to be ...
Chronic graft-vs-host disease (GVHD) is a cause of late morbidity and mortality after allogeneic stem cell transplant. During ...
Genmab A/S today announced that more than 20 abstracts evaluating epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, across lines of therapy and B-cell non-Hodgkin's ...
"As a registered nurse with severe obstructive sleep apnea (OSA), do NOT ignore snoring. Untreated sleep apnea is very ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that it will showcase 46 abstracts, ...
First-in-Human Phase 1 data for allogeneic CAR-T cell therapy for NHL to be featured in oral session ...
Nov. 3, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the third ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback